The Role and Mechanism of Action of Regdanvimab in the Treatment of COVID-19

Abstract

The neutralizing antibody can be one of the promising treatments to fight the COVID-19 pandemic, based on the previous coronavirus outbreak. Regdanvimab (CT-P59) is a new monoclonal antibody developed by Celltrion that targets the receptor-binding domain (RBD) in the spike protein of SARS-CoV-2. After the previous monoclonal antibodies (mAbs) approved by WHO, casirivimab, and imdevimab, regdanvimab has now received its first approval as the COVID-19 treatment in elderly patients aged >50 years old or at least one medical condition, including obesity, cardiovascular disease, chronic lung disease, diabetes, and ongoing immunosuppressive agents, and adult patients with moderate symptoms in South Korea. The attachment of regdanvimab to the RBD directly covers the SARS-CoV-2 binding surface area to the ACE2, which eventually inhibits the virus recognition and entry into the host cell. Therefore, regdanvimab can be used to reduce the viral titer in combination with the present antiviral therapies. The clinical trials of regdanvimab reported that a single intravenous administration of regdanvimab is associated with a shorter recovery time and a lower hospital admission and oxygen therapy requirement than the placebo.